Lauren Barnes Joins Ossium Health’s Board of Directors
Ossium Health Secures Series C to Expand Bone Marrow Bank, Advance Clinical Trials to Treat Life-Threatening Blood and Immune Diseases
Ossium Health Awarded $3.46M in Funding from the California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)
SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, Inc., a clinical-stage bioengineering company developing cellular therapeutics to revolutionize treatment of blood, immune, and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease. Ossium plans to initiate patient screening and enrollment in a multi-center Phase 1 clinical trial evaluating OSSM-001 by the end of 2022.